&w=3840&q=100)
Glenmark set to launch blood cancer treatment drug Brukinsa in India
Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies.
Approved in over 70 countries
Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments.
The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs.
In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications.
"We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals.
'This launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety. It underscores Glenmark's ongoing commitment to providing effective and advanced treatments for patients with haematological malignancies," he added.
Global partnership expands to India
Adam Roach, Senior Vice President and Head of the Japan and Asia Pacific region at BeiGene, commented: 'The introduction of Brukinsa in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region.'
'We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
24-06-2025
- Business Standard
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients". Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said. It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard
24-06-2025
- Business Standard
Glenmark Pharma launches TEVIMBRA in India
Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal antibody created by BeiGene, now BeOne Medicines, which focuses on oncology. TEVIMBRA is intended for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) when combined with chemotherapy. It is also approved for second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as a standalone therapy. The launch signifies Glenmark's entry into the immuno-oncology market in India. This strategic step aims to expand its innovative oncology offerings. NSCLC represents more than 80% of lung cancer cases, while ESCC is the most common type of esophageal cancer in India. TEVIMBRA is already approved and available in major markets such as the US, the EU, Australia, and China. The therapy specifically targets PD-1 receptors, helping to restore T-cell function while reducing off-target immune suppression. It has shown strong effectiveness and a good safety profile in several key Phase 3 trials across a variety of solid tumors. Alok Malik, President and Business Head India Formulations, Glenmark Pharmaceuticals, said, At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access TEVIMBRA, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers that are difficult to treat. Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across branded, generic, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. Shares of Glenmark Pharmaceuticals rose 0.78% to Rs 1,699.25 on the BSE.
Business Standard
24-06-2025
- Business Standard
RateGain appoints Sanchit Garg to spearhead its Rev-AI and Car biz
RateGain Travel Technologies announced the appointment of Sanchit Garg as Executive Vice President & General Manager - Rev-AI & Car. Sanchit will spearhead the global strategy, operations, and growth for RateGain's Rev-AI and Car business, collaborating with regional leaders to drive the next phase of innovation and high performance. Sanchit is an entrepreneur at heart, with deep experience across e-commerce, sales, technology, and strategy. Over the years, he has built and scaled ventures and teams with a unique blend of product vision, business acumen, and strong P&L ownership. Known for successfully leading both early-stage startups and scale-up journeys, Sanchit brings an empathetic, collaborative leadership style and a passion for solving complex business problems. He previously founded Rartogo, a Sequoia-backed cross-border platform for mid-market customers in the US and EMEA, scaling it to $7M in annual recurring revenue. At Lazada (an Alibaba Group company), he led the $250M Smartphones category, working closely with brands like Apple and Samsung. At Group ONE, he served as Global Head of Sales, growing revenues to $80M ARR across the US, EMEA, and APAC. Sanchit started his career as a software engineer before joining McKinsey & Company, where he worked across India and the US.
